Sellas Life Sciences

Yahoo Finance • 16 days ago

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds

NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of c... Full story

Yahoo Finance • 16 days ago

Solaris Strengthens Community Partnerships and Advances Key Milestones at Warintza Project

HIGHLIGHTS: Landmark agreement signed with PSHA, completing formal partnerships with all Indigenous organisations surrounding the Warintza Project Pre-Feasibility Study advancing with positive momentum, incorporating updated Mineral Resou... Full story

Yahoo Finance • last month

How To YieldBoost Brightstar Lottery To 16.3% Using Options

Shareholders of Brightstar Lottery PLC (Symbol: BRSL) looking to boost their income beyond the stock's 4.9% annualized dividend yield can sell the June 2026 covered call at the $17 strike and collect the premium based on the $1.50 bid, whi... Full story

Yahoo Finance • 2 months ago

SELLAS Life Sciences Group Inc (NASDAQ:SLS) Reports Q2 2025 Earnings: Narrower Loss and Clinical Progress Amid Revenue Challenges

SELLAS Life Sciences Group Inc (NASDAQ:SLS [https://www.chartmill.com/stock/quote/SLS]) reported its second-quarter 2025 financial results, with earnings per share (EPS) of -$0.07, slightly better than the analyst consensus estimate of -$0... Full story

Yahoo Finance • 2 months ago

SELLAS Life Sciences Gets Positive IDMC Nod To Continue Phase 3 Trial Of AML Treatment

(RTTNews) - SELLAS Life Sciences Group, Inc. (SLS), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, Thursday announced that the Independent Data Monitor... Full story

Yahoo Finance • 2 months ago

IDMC recommends continuation of Phase 3 AML trial for galinpepimut-S

NEW YORK - SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), a clinical-stage biotech company with a market capitalization of $159 million, announced Thursday that the Independent Data Monitoring Committee (IDMC) has recommended continuing th... Full story

Yahoo Finance • 2 months ago

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

-        Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events - NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceu... Full story

Yahoo Finance • 2 months ago

SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study

The Trial Exceeded Target Overall Response Rate (ORR) of 20%, with 44% Response Rate Among Patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML MR) Treated at Optimal Dose of 30 mg Twice a Week (BIW) and 50% in AML MR w... Full story

Yahoo Finance • 3 months ago

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of c... Full story

Yahoo Finance • 4 months ago

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of c... Full story

Yahoo Finance • 4 months ago

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

- ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer – - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in the US: 55% ASXL1m Frequency – NEW YORK, J... Full story

Yahoo Finance • 4 months ago

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of ca... Full story

Yahoo Finance • 4 months ago

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

– Announced Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 (tambiciclib) in Relapsed/Refractory (r/r) Acute Myeloid Leukemia (AML) Demonstrating 8.9 mOS in AML-MRC and 8.8 mOS in All r/r to Venetoclax-Based... Full story

Yahoo Finance • 5 months ago

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of c... Full story

Yahoo Finance • 6 months ago

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

- 8.9 Months Median Overall Survival (mOS) in Patients with AML-Myelodysplasia-Related Changes (AML-MRC) and 8.8 mOS in All Relapsed or Refractory to Venetoclax-Based Regimens Patients; Surpassing Historical Benchmark of 2.5 Months - - Ov... Full story

Yahoo Finance • 6 months ago

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

– Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with Next and Final Analysis Planned Upon Reaching 80 Events, Anticipated in 2025 – – Reported Po... Full story

Yahoo Finance • 7 months ago

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

- Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in Difficult-to-Treat Non-GCB DLBCL (ABC DLBCL) Patients - - Median Overall Survival Not Reached Yet – 67% of Pat... Full story

Yahoo Finance • 8 months ago

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of ca... Full story

Yahoo Finance • 8 months ago

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

- REGAL Successfully Passes Event-Driven (60 Deaths) Interim Analysis for Efficacy, Futility, and Safety: The Independent Data Monitoring Committee (IDMC) Recommended Continuation of the Clinical Trial Without Modification – - Based on a... Full story

Yahoo Finance • 2 years ago

SELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia

NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of c... Full story